Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4381-4390 Newer>

The Motley Fool November 28, 2007 Brian Orelli	Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells.
The Motley Fool November 28, 2007 Brian Orelli	Abbott's Future as a Stent Maker The FDA likes Abbott's new drug-eluting stent; it seems likely the advisory committee will recommend that it be approved.
The Motley Fool November 27, 2007 Brian Orelli	Ploughing Into Acquisition Rewards Schering-Plough reaps its first New Drug Application from its purchase of Organon. Investors, take note.
The Motley Fool November 27, 2007 Brian Lawler	Cardiome Makes Them Wait Cardiome Pharma announces a delay in the release of data on an oral version of its lead heart drug. Investors, take note.
The Motley Fool November 27, 2007 Brian Orelli	Second Chance for Merck's MEVACOR Merck licenses the rights to an over-the-counter version of its cholesterol-lowering drug MEVACOR to GlaxoSmithKline, but the deal is far from done. Investors, take note.
Wired November 27, 2007 Scott Carney	Inside India's Underground Trade in Human Remains The need to study human bones in medicine is well established. The need to obtain the informed consent of people whose bones are studied is not. The reemergence of India's international bone trade reflects the tension between these requirements.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool November 26, 2007 Brian Lawler	Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note.
The Motley Fool November 23, 2007 Brian Orelli	Almost at Par Par Pharmaceutical releases 2007 Q1 and Q2 earnings simultaneously; Q3 results should be following soon.
BusinessWeek December 3, 2007 Grow & Berner	Fresh Pain for the Uninsured As doctors and hospitals turn to GE, Citi, and smaller rivals to finance patient care, the sick pay much more.
<Older 4381-4390 Newer> Return to current articles.